REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
They know they have to get the P2 trials right and the bio-markers and tests look like they will be critical.
I wouldn't be surprised if they postponed the P2 further until they can be sure of passing them with the right bio-markers and tests to identify the most suitable patients.
They want to pass the P2 tests and this is the last roll of the dice.
Doc.Dan - Do you have doubts now? Looking at the RM interview he looks burned but well fed. I suspect they know this is their last roll of the dice. So, are desperate for it to work. If this fails, TFG will probably put someone on the board and have a a fire sale.
I just watched the interview and RM was spot on. Targeting the right patients is critical for success now.
He was candid about what would happen if they just repeated a Clinical Trial without targeting.
I suspect they are waiting for more tests to be developed, bio-markers to be identified and the results of the observational studies to be analysed.
They know this is their last chance and they want to succeed for personal as well as professional reasons.
Hopefully, the new genetic tests (from Casanova Labs, etc.) will target the right patients.
If the P2 trials are successful, I will sell up. I do not trust the management to run a P3.
I am over-extended in this share.
GLALTI
Yes, I recall someone stating that BP and Gov wouldn't be interested in SNG until there is further data. It was recorded during a conversation with a director after the main AGM presentation this year. The phrase "opening the flood gates" was used.
So, we have to wait for P2 results.
Given the situation, I am prepared to wait until there are effective tests (e.g. from UNIVERSAL and Cazanova) to determine suitable patients to ensure a greater chance of success.